Patient-reported outcomes of therapy with two brands of ibuprofen
Fuente:
Redalyc
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Artículo científico |
| Lingua: | en |
| Pubblicazione: |
Centro de investigaciones y Publicaciones Farmacéuticas
2008
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1876450315596726272 |
|---|---|
| author | Azuka C. Oparah |
| author_facet | Azuka C. Oparah |
| contents | Patient-reported outcomes of therapy with two brands of ibuprofen Azuka C. Oparah Lucky L. Nwidu Joshua F. Eniojukan Medicina Nigeria Ibuprofen Treatment Outcome Therapeutic Equivalency Objective: To investigate patients reported outcome following medication with two brands of 400 mg ibuprofen used to alleviate musculoskeletal pains.Methods: Adult peasant manual laborers (85) who met criteria were randomly assigned to receive either of the brands (A or B). Data on painalleviation were gathered using the Short-Form McGill Pain Questionnaire (SF-MPQ), Visual Analogue Scale (VAS), Present Pain Intensity (PPI), and Clinical Global Impression of Improvement (CGII) scales. Interval data obtained from the two brands were compared using the Students t-test at95% confidence interval.Results: There were 42 participants, mean age=29.2 (SD=1.37) assigned to brand A and 43 (mean age=28.8 SD=1.14) in brand B of ibuprofen 400 mg. Brand B was consistently rated higher thanbrand A. Scores for medication efficacy were 10.4 (SD=1.65) (brand A) and 11.4 (SD=1.68) (brand B); t=2.768, P=0.007. Alleviation of pain symptoms:10.8 (SD=1.64) and 11.6 (SD=1.72); t = 2.194, P=0.031. Similarly, rated scores on the impact of pain on quality of life were 10.5 (SD=2.00) and 12.1 (SD=1.85); t=3.830, P<0.001. There was a reduction in Present Pain Intensity scores by 32.7% and 34.3% for Brand A and brand B participantsrespectively. The decrease in Visual Analog pain scale score was 35.9% and 37.3% for brand A and brand B participants respectively. The decrease in SF-MPQ was by 85.1% and 69.9% for the brand A and brand B groups respectively. The clinical global impression of improvement for both groups of patients indicated an improvement rate of 71.4% and 61.9% for brand A and 81.4% and 74.4% forbrand B participants... 2008 artículo científico 1885-642X https://www.redalyc.org/articulo.oa?id=69060305 en http://www.redalyc.org/revista.oa?id=690 Pharmacy Practice application/pdf Centro de investigaciones y Publicaciones Farmacéuticas Pharmacy Practice (España) Num.3 Vol.6 |
| format | Artículo científico |
| id | redalyc_69060305 |
| institution | Redalyc |
| language | en |
| publishDate | 2008 |
| publisher | Centro de investigaciones y Publicaciones Farmacéuticas |
| spellingShingle | Patient-reported outcomes of therapy with two brands of ibuprofen Azuka C. Oparah Medicina Nigeria Ibuprofen Treatment Outcome Therapeutic Equivalency Patient-reported outcomes of therapy with two brands of ibuprofen Azuka C. Oparah Lucky L. Nwidu Joshua F. Eniojukan Medicina Nigeria Ibuprofen Treatment Outcome Therapeutic Equivalency Objective: To investigate patients reported outcome following medication with two brands of 400 mg ibuprofen used to alleviate musculoskeletal pains.Methods: Adult peasant manual laborers (85) who met criteria were randomly assigned to receive either of the brands (A or B). Data on painalleviation were gathered using the Short-Form McGill Pain Questionnaire (SF-MPQ), Visual Analogue Scale (VAS), Present Pain Intensity (PPI), and Clinical Global Impression of Improvement (CGII) scales. Interval data obtained from the two brands were compared using the Students t-test at95% confidence interval.Results: There were 42 participants, mean age=29.2 (SD=1.37) assigned to brand A and 43 (mean age=28.8 SD=1.14) in brand B of ibuprofen 400 mg. Brand B was consistently rated higher thanbrand A. Scores for medication efficacy were 10.4 (SD=1.65) (brand A) and 11.4 (SD=1.68) (brand B); t=2.768, P=0.007. Alleviation of pain symptoms:10.8 (SD=1.64) and 11.6 (SD=1.72); t = 2.194, P=0.031. Similarly, rated scores on the impact of pain on quality of life were 10.5 (SD=2.00) and 12.1 (SD=1.85); t=3.830, P<0.001. There was a reduction in Present Pain Intensity scores by 32.7% and 34.3% for Brand A and brand B participantsrespectively. The decrease in Visual Analog pain scale score was 35.9% and 37.3% for brand A and brand B participants respectively. The decrease in SF-MPQ was by 85.1% and 69.9% for the brand A and brand B groups respectively. The clinical global impression of improvement for both groups of patients indicated an improvement rate of 71.4% and 61.9% for brand A and 81.4% and 74.4% forbrand B participants... 2008 artículo científico 1885-642X https://www.redalyc.org/articulo.oa?id=69060305 en http://www.redalyc.org/revista.oa?id=690 Pharmacy Practice application/pdf Centro de investigaciones y Publicaciones Farmacéuticas Pharmacy Practice (España) Num.3 Vol.6 |
| title | Patient-reported outcomes of therapy with two brands of ibuprofen |
| topic | Medicina Nigeria Ibuprofen Treatment Outcome Therapeutic Equivalency |
| url | https://www.redalyc.org/articulo.oa?id=69060305 |